Topic summary

About the Tirzepatide category

Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki

This is a generated summary. It shows the 5 most-liked posts from a topic of 7, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

s.leclercTL4 Moderator21 Jun 2025#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by hana.sato on 13 Oct 2025.

6 Sep 2025 — s.leclerc: Removed a claim that the cited source did not support.
9 Jul 2025 — mira.patel: Replaced an unsourced figure with the published one and cited it.
13 Oct 2025 — hana.sato: Added the worked example and a unit label to the table header.

Editors: s.leclerc, mira.patel, hana.sato

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

Questions specific to tirzepatide, with the units and the context stated.
Reports and datasets, with the collection method stated.
Disagreement about the substance, conducted in public.

What belongs elsewhere

Anything urgent belongs in Safety, immediately, and not here.
Anything about how this site works belongs in Meta.
Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

38 likes 13mo

desiccant_notesTL2Member23 Jun 2025#3

As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic list shows you what is recent. The tags show you what is settled.

2 likes 13mo

s.roosTL2 Moderator24 Jun 2025#4

Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note.

9 likes 13mo

MakinenTL2Member25 Jun 2025#5

The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a starting dose with the purpose of a maintenance dose leads to false conclusions about efficacy.

28 likes 13mo

m.wanjalaTL1Member26 Jun 2025#7

This follows post #4 rather than contradicting it.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

5 likes 13mo

Read the full topic (7 posts)

This topic was referenced in

Revisiting: Why tirzepatide titration schedules have more steps than semaglutide'sCompounds › Tirzepatide · 101 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…	+119	136	5.6k	2mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…		4	42k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…	+12	16	11k	7mo

Related topics — sharing the tags tirzepatide, SURMOUNT programme, SURPASS programme

Topic	Participants	Replies	Views	Activity
Escalating every six weeks instead of four: what I observed over eight months — one year on Practice › Dosing & titration missed dose semaglutide dose reduction titration On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…	+55	59	9.1k	10mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of…	+130	137	11k	19mo
Micro-titration: a disputed topic, argued properly Practice › Dosing & titration titration dose reduction worked example tirzepatide Solved Wiki Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. A question about technique rather than about dose. I have been doing the…	+99	110	61k	2d
SURPASS-2 and the comparator dose question that will not go away — what changed since Compounds › Tirzepatide SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…	+2	6	5.5k	7h
Biased agonism: a real phenomenon, an over-used explanation Pharmacology › Receptor biology semaglutide retatrutide long read tirzepatide Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…	+130	135	23k	16mo